Please try another search
For the three months ended 31 March 2022, Agimexpharm Pharmaceutical JSC revenues increased 26% to VND161.63B. Net income increased 43% to VND12B. Revenues reflect Gross Sales increase of 26% to VND165.04B. Basic Earnings per Share excluding Extraordinary Items increased from VND553.80 to VND668.01.
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 161631.71 | 143574.98 | 127496.75 | 122144.51 |
Gross Profit | 58345.81 | 55782.43 | 42972.69 | 43209.31 |
Operating Income | 14958.21 | 12484.73 | 9414.05 | 8629.34 |
Net Income | 12003.6 | 10263.82 | 7572.19 | 6994.84 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 750689.29 | 670869.62 | 628778.66 | 619923.71 |
Total Liabilities | 445206.51 | 438640.03 | 406812.88 | 405530.13 |
Total Equity | 305482.78 | 232229.59 | 221965.77 | 214393.58 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -12616.13 | 14999.09 | 27437.97 | 19910.83 |
Cash From Investing Activities | -6043.05 | -23440.73 | -13749.99 | -6559.65 |
Cash From Financing Activities | 55026.58 | 17752.11 | -11585.08 | -13228.1 |
Net Change in Cash | 36367.4 | 9308.42 | 2102.73 | 16509.48 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review